Tvardi Therapeutics (TVRD) Operating Expenses: 2013-2017
Historic Operating Expenses for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to $13.0 million.
- Tvardi Therapeutics' Operating Expenses rose 10.05% to $13.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $68.1 million, marking a year-over-year increase of 48.45%. This contributed to the annual value of $58.5 million for FY2016, which is 101.74% up from last year.
- As of Q3 2017, Tvardi Therapeutics' Operating Expenses stood at $13.0 million, which was up 34.50% from $9.6 million recorded in Q2 2017.
- Tvardi Therapeutics' Operating Expenses' 5-year high stood at $23.2 million during Q1 2017, with a 5-year trough of $1.5 million in Q1 2013.
- Moreover, its 3-year median value for Operating Expenses was $11.0 million (2016), whereas its average is $12.1 million.
- In the last 5 years, Tvardi Therapeutics' Operating Expenses spiked by 138.34% in 2014 and then declined by 28.14% in 2017.
- Quarterly analysis of 5 years shows Tvardi Therapeutics' Operating Expenses stood at $3.1 million in 2013, then surged by 70.57% to $5.2 million in 2014, then surged by 85.31% to $9.7 million in 2015, then spiked by 129.37% to $22.3 million in 2016, then increased by 10.05% to $13.0 million in 2017.
- Its Operating Expenses stands at $13.0 million for Q3 2017, versus $9.6 million for Q2 2017 and $23.2 million for Q1 2017.